Table 3.
Studies reporting postoperative HDR interventional radiotherapy (brachytherapy) in eyelid cancers.
| HDR-IRT in Eyelid Cancers | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Author | Year | Country | n. of patients | Intent: Radical, Adjuvant, or Salvage | Histology | T stage | Fractionation | Total dose | EQD2 (α/β=10) | Follow-up (months) | Outcome |
| Laskar et al. 26 | 2015 | India | 8 | 100% A a | SebC 50% SCC 37.5% BCC 12.5% |
T4: 37.5% Other than T4: 62.5% |
3 Gy B.I.D. for 7 fr 3.5 Gy B.I.D. for 10 fr |
21 Gy 35 Gy |
22.8 Gy 39.4 Gy |
35 | LC 100% |
| Mareco et al. 27 | 2015 | Portugal | 17 | 12% R 71% A b 17% S |
SCC 94% BCC 6% |
Tis: 6% T1: 46% T2a: 18% T2b: 18% T3a: 12% |
median 10 B.I.D. fr (range 9 to 11) |
median 42.8 Gy (range 32 to 50 Gy) | 50.9 Gy | 40 | LC 94.1% |
| Cisek et al. 28 | 2021 | Poland | 28 | 57% R 14% A c 29% S |
BCC 86% SCC 14% |
T1: 82% T2: 18% |
5 Gy B.I.D. for 9 fr 3.5 Gy B.I.D. for 14 fr |
45 Gy 49 Gy |
56.3 Gy 55.1 Gy |
24 | LC 96.5% |
| Cuffaro et al. | 2023 | Italy | 10 | 100% A b | SebC 30% BCC 30% SCC 20% Melanoma 20% |
T2b: 10% T3b-c: 40% T4a: 50% |
3.4 Gy B.I.D. for 10 fr 3.5 Gy B.I.D. for 14 fr |
34 Gy 49 Gy |
38.0 Gy 55.1 Gy |
10 | LC 80% |
aIncludes negative or close margins.
bIncludes close or positive margins.
cIncludes positive margins.